AXSM Axsome Therapeutics announces FDA Acceptance of new drug application for axs-12 for the treatment of cataplexy in narcolepsy Axsome The

AXSM Axsome Therapeutics announces FDA Acceptance of new drug application for axs-12 for the treatment of cataplexy in narcolepsy Axsome Therapeutics - FDA sets pdufa target action date of may 1, 2027 for axs-12 NDA - FDA does not plan advisory committee meeting for axs-12 NDA